From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Is 4.3p as a target for the Zoetic fraud too high? Green Roads deal suggests 0.5p is more accurate

By Tom Winnifrith | Wednesday 28 April 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


To be fair, I never said that my target for this fraud was 4.3p, I just explained how, if you made wildly optimistic assumptions about current year sales then on a read-across from Love Hemp, 4.3p was fair value. I actually think 0p is fairer as Zoetic International (ZOE) is a fraud which will eventually run out of other people’s money. But a corporate deal in the US suggests yesterday that, maybe, fair value is 0.5p.


Canadian listed Valens has bought Green Roads, a privately owned Florida company which was seen as a pioneer of US CBD products. It has a diverse portfolio of products (far broader than Zoetic), has not lied to consumers, investors and regulators, it is EBITDA profitable and its goods are sold in 7,000 US stores. There are plans to increase that rapidly. It also makes its own product and supplies raw material to others. It has invested heavily in creating brand awareness unlike Zoetic whose products have zero brand awareness.


The run rate revenues are £16 million a year. Zoetic’s run rate is something of a mystery as, for some reason which I am sure you can guess, it neglected to include any sales numbers in its FY trading statement. But let’s be charitable – given H1 sales were just £54,000 and say the annualised run rate is £500,000.


What did Valens pay to buy a quality operator? In a cash and shares deal, £29 million or 1.8 times run rate. Zoetic, even at 61.5p (and falling fast), is capitalised at £121 million yet it has zero brand awareness, sod all sales, says it will be in 3,500 stores by July but there is no proof of this, is drowning in red flags.


On my uber-generous assumption about its current sales run rate, it should be valued on a read-across at £900,000 or c0.5p per share.


So that is your valuation range:

0p – my target as this is a fraud
0.5p – based on the latest corporate activity
4.3p – based on a Love Hemp read-across and optimistic sales assumptions


Take your pick. At 61.5p the shares are a monumental sell especially given how leveraged the bulls are on this one. This could be GameStop in reverse as those margin calls kick in.

This story is available to all readers
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:33:16